Alder BioPharma (ALDR) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Alder BioPharmaceuticals Announces Third Quarter 2016 Financial and Operating Results
October 27, 2016 4:02 PM EDTCompany Finalizes ALD403 Pivotal Program Design and Confirms Planned Initiation of PROMISE 2 Phase 3 Study in 2016
Top-Line ALD403 PROMISE 1 Phase 3 Data Expected in First Half of 2017Â
BOTHELL, Wash., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced its financial results for the third quarter ended Sept. 30, 2016, and provided a corporate and clinical update.
As part of this update, the company reported positive outcomes from discussions with the U.S. Food and Drug Administration (FDA)... More
